We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00325195
Recruitment Status : Completed
First Posted : May 12, 2006
Results First Posted : February 25, 2011
Last Update Posted : February 28, 2011
Information provided by:
Savient Pharmaceuticals

Tracking Information
First Submitted Date  ICMJE May 10, 2006
First Posted Date  ICMJE May 12, 2006
Results First Submitted Date  ICMJE October 13, 2010
Results First Posted Date  ICMJE February 25, 2011
Last Update Posted Date February 28, 2011
Study Start Date  ICMJE May 2006
Actual Primary Completion Date October 2007   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 1, 2011)
Plasma Uric Acid (PUA) Responder [ Time Frame: Months 3 and 6 ]
PUA Responder was defined as a participant who achieved and maintained plasma uric acid concentrations < 6 mg/dL for at least 80% of the time during months 3 and 6 combined. Participants who withdrew from the study before month 6 were considered non-responders.
Original Primary Outcome Measures  ICMJE
 (submitted: May 10, 2006)
plasma uric acid (PUA) concentrations
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 24, 2011)
  • Reduction in Tophus Burden [ Time Frame: Baseline and Final Visit (6 months or LOCF) ]
    percentage of tophaceous subjects who demonstrated a complete resolution (100 % decrease in measured area or complete disappearance)of at least one tophus in the absence of other tophus progression or new tophi, as assessed by a blinded Central Reader using standardized digital photographs and image analysis software.
  • Percentage of Subjects With Gout Flare Per 3-month Period [ Time Frame: Months 1-3 and Months 4-6 ]
    Percent of participants reporting a gout flare during Months 1-3 and Months 4-6. Denominator during the respective period was based upon number of participants during that period.
  • Change in Number of Swollen Joints [ Time Frame: Baseline and Final Visit (Month 6 or LOCF) ]
    Change from Baseline to Month 6 (or last observation carried forward)in number of swollen joints per subject. Values were inputed using last observation carried forward analysis for subjects who did not complete the studies.
  • Change in Number of Tender Joints [ Time Frame: Baseline and Final Visit (Month 6 or LOCF) ]
    Change from Baseline to Month 6 (or last observation carried forward) in number of tender joints per participant
  • Change in Patient Reported Outcomes of Pain, Physical Function and Quality of Life [ Time Frame: Baseline to Final Visit (Month 6 or LOCF) ]
    Health Assessment Questionnaire(HAQ: VAS pain scale where 0 (no pain)-100 (severe pain); HAQ disability index (HAQ-DI) on a scale from 0(no disability) to 3 (completely disabled), and a unit change of > or =0.22 is considerd a mimimal clinically important difference(MCID). SF-36 Physical Component Summary Score (SF36-PCS), a composite score where 0 is the worst score and 100 the best possible, and where a change of > or =2.5 units in the PCS is considered a MCID.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 10, 2006)
  • reduction in tophus burden
  • frequency of gout flares
  • number of swollen and tender joints
  • patient reported outcomes utilizing the SF-36 and HAQ-DI
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Official Title  ICMJE Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout
Brief Summary These are two replicate studies to evaluate the safety and efficacy of PEG (polyethylene glycol)-uricase in controlling the uric acid level in symptomatic gout patients with high uric acid levels who are unable to take standard gout therapies, or for whom those therapies have been unsuccessful in controlling their uric acid level.
Detailed Description

The primary objective of each of the studies is to demonstrate superiority in the response rate (control of uric acid levels to below 6 mg/dL) in the PEG-uricase treatment groups compared to the placebo-control group.

While reduction or resolution of tophi have been reported in the setting of prolonged urate-lowering therapy, there is photographic and additional anecdotal evidence from the Phase 2 PEG-uricase study of resolution or significant reduction of tophi after 3 months of therapy. Therefore, an assessment of changes in tophi over time will be conducted through the use of digital photographs obtained in a standardized manner from all subjects during the study. The effect on other clinical outcomes, including quality of life, health-related disability measures, gout flares and the number of swollen and tender joints will also be compared between the treatment groups and control group. Subjects will be randomized to one of the three treatment arms in a 2:2:1 ratio: 8 mg PEG-uricase every 2 weeks; 8 mg PEG-uricase every 4 weeks; or placebo. All subjects will receive an intravenous infusion (PEG-uricase or placebo) every two weeks in order to maintain the blind throughout the study. Study duration is approximately 26 weeks, including two weeks for screening and 24 weeks (6 months) of treatment.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Gout
Intervention  ICMJE
  • Other: placebo
    placebo by intravenous infusion every 2 weeks
  • Biological: pegloticase
    8 mg pegloticase by intravenous infusion
    Other Names:
    • PEG-uricase
    • Puricase
Study Arms  ICMJE
  • Experimental: q2 wks
    8 mg pegloticase every 2 weeks
    Intervention: Biological: pegloticase
  • Experimental: q4 wks
    8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)
    Intervention: Biological: pegloticase
  • Placebo Comparator: placebo
    placebo every 2 weeks
    Intervention: Other: placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 1, 2011)
Original Enrollment  ICMJE
 (submitted: May 10, 2006)
Actual Study Completion Date  ICMJE December 2007
Actual Primary Completion Date October 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Outpatients of either gender, age 18 or older ( no upper age limit).
  2. Patient is hyperuricemic: screening serum uric acid must be ≥8 mg/dL.
  3. Patient has symptomatic gout (presence of at least 3 gout flares in the 18 months prior to entry, or at least one gout tophus, or gouty arthritis).
  4. Conventional therapy is contraindicated or has been ineffective in this patient, i.e., patient has a history (either by medical record or patient interview) of hypersensitivity or of failure to normalize SUA with at least 3 months treatment with allopurinol at the maximum labeled dose (800 mg/dL in the U.S.), or at a medically appropriate lower dose based on dose-limiting toxicity or dose-limiting co-morbidity.
  5. Patient is willing and able to give informed consent and adhere to visit/protocol schedules (informed consent must be given before the first study procedure is performed, including washout).
  6. If the patient is a woman of childbearing potential, she must have had a negative screening serum pregnancy test and must use a medically approved form of birth control during her participation in the protocol. Such methods include oral, injectable or implantable contraceptives; IUDs and barrier contraceptives in combination with spermicide. (If male or surgically sterile, check N/A.)

Exclusion Criteria:

  1. The patient has unstable angina.
  2. The patient has uncontrolled arrhythmia.
  3. The patient has non-compensated congestive heart failure.
  4. The patient has uncontrolled hypertension (above 150/95).
  5. The patient has a history of end stage renal disease requiring dialysis.
  6. The patient has hemoglobin < 8 g/dL (males) or < 7 g/dL (females).
  7. The patient is an organ transplant recipient
  8. The patient has had prior treatment with PEG-uricase, or other recombinant uricase, or any concomitant therapy with a PEG-conjugated drug.
  9. The patient has had a gout flare at screening that is resolved for less than one week prior to first treatment with study drug (exclusive of chronic synovitis/ arthritis).
  10. The patient has glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  11. The patient has a history of anaphylactic reaction to a recombinant protein or porcine product, or hypersensitivity to PEG.
  12. The patient is pregnant or breast feeding.
  13. The patient has taken an investigational drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study.
  14. The patient has a known allergy to urate oxidase or PEGylated products.
  15. The patient has any other medical or psychological condition which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Mexico,   United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00325195
Other Study ID Numbers  ICMJE C0405 & C0406
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Savient Pharmaceuticals, Inc
Original Responsible Party Not Provided
Current Study Sponsor  ICMJE Savient Pharmaceuticals
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director, MD Savient Pharmaceuticals, Inc.
PRS Account Savient Pharmaceuticals
Verification Date February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP